Original Query: ALL
Previous Study | Return to List | Next Study

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00146042
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : October 5, 2012
Genentech, Inc.
Information provided by (Responsible Party):
University of Michigan Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : March 2004
  Study Completion Date : March 2005